Saniona AB - Asset Resilience Ratio
Saniona AB (SANION) has an Asset Resilience Ratio of 85.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Saniona AB's Asset Resilience Ratio has changed over time. Check SANION capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Saniona AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SANION market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr580.82 Million | 85.45% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr580.82 Million | 85.45% |
Asset Resilience Insights
- Very High Liquidity: Saniona AB maintains exceptional liquid asset reserves at 85.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Saniona AB Industry Peers by Asset Resilience Ratio
Compare Saniona AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Saniona AB (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Saniona AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 85.45% | Skr580.82 Million ≈ $62.51 Million |
Skr679.74 Million ≈ $73.15 Million |
-3.82pp |
| 2024-12-31 | 89.26% | Skr303.26 Million ≈ $32.64 Million |
Skr339.73 Million ≈ $36.56 Million |
+40.99pp |
| 2023-12-31 | 48.27% | Skr30.96 Million ≈ $3.33 Million |
Skr64.14 Million ≈ $6.90 Million |
-22.38pp |
| 2022-12-31 | 70.65% | Skr108.59 Million ≈ $11.69 Million |
Skr153.70 Million ≈ $16.54 Million |
-10.50pp |
| 2021-12-31 | 81.15% | Skr357.27 Million ≈ $38.45 Million |
Skr440.25 Million ≈ $47.38 Million |
-1.45pp |
| 2020-12-31 | 82.60% | Skr571.77 Million ≈ $61.53 Million |
Skr692.18 Million ≈ $74.49 Million |
+33.47pp |
| 2019-12-31 | 49.13% | Skr47.17 Million ≈ $5.08 Million |
Skr96.00 Million ≈ $10.33 Million |
-11.87pp |
| 2018-12-31 | 61.00% | Skr50.68 Million ≈ $5.45 Million |
Skr83.08 Million ≈ $8.94 Million |
+27.32pp |
| 2017-12-31 | 33.68% | Skr16.29 Million ≈ $1.75 Million |
Skr48.38 Million ≈ $5.21 Million |
-41.58pp |
| 2016-12-31 | 75.26% | Skr53.26 Million ≈ $5.73 Million |
Skr70.77 Million ≈ $7.62 Million |
-- |
About Saniona AB
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more